Platinum levels were measured at days 0, 7, 14, 21 and 28.
Complete blood cell (CBC) counts, body weight, local toxicity and side effects were also evaluated at the time of platinum measurement at days 0, 7, 14, 21 and 28.
CSR released carboplatin steadily over 30 days.
Neutropenia was noted as Grade 3 in one dog (14%) and Grade 4 in two dogs (29%) at day 14, and Grade 4 in one dog (14%) at day 21.
Thrombocytopenia was noted as Grade 2 in four dogs (57%), Grade 3 in one dog (14%) and Grade 4 in one dog (14%) at day 14; Grade 2 in two dogs (29%) and Grade 3 in one dog (14%) at days 21 and 28.
Grade 1 lethargy in one dog (14%) and Grade 1 nausea in dog (14%) occurring within 7 days after administration.
No obvious local injection site reactions were noted.
CSR administered at 350 mg m−2 intramuscularly resulted in a steady release over 30 days.
Myelosuppression (Grade 4) was noted in 86% of patients. CSR released the drug slowly and steadily, however additional studies are needed to assess acceptable dosage requirements.
Source: Tansey Baldwin, C., Zwahlen, C. H., Kirschner, S. and Nakamura, R. K. (2016), Evaluation of carboplatin sustained-release delivery system in dogs with cancer. Veterinary Medicine and Scienc. doi: 10.1002/vms3.26
|
